Table 1:
Demographics and disease characteristics according to ursodeoxycholic acid use
| Previously on UDCA (n = 50) | Currently on UDCA (n = 1001) | Never on UDCA (n = 74) | |
|---|---|---|---|
|
Sex, no. (%) Female Male |
46 (92) 4 (8.0) |
903 (90.3) 97 (9.7) |
65 (87.8) 9 (12.2) |
| Year of diagnosis, median (25th–75th percentile)* | 2008 (2002–2014) | 2010 (2006–2013) | 2014 (2009–2015) |
| AMA-positive, no. (%)† | 31 (62.0) | 803 (80.4) | 55 (75.3) |
|
Age at last visit, y,‡ median (25th–75th percentile) <40, no. (%) 40–49, no. (%) 50–59, no. (%) 60–69, no. (%) ≥70, no. (%) |
62.5 (56.6–69.4)
2 (4.1) 4 (8.2) 13 (26.5) 19 (38.8) 11 (22.4) |
61.7 (54.7–68.7)
24 (2.5) 105 (10.8) 300 (30.8) 342 (35.1) 202 (20.8) |
58.7 (51.6–66.6)
9 (12.2) 7 (9.5) 25 (33.8) 21 (28.4) 12 (16.2) |
|
Time from diagnosis to last visit, y,§ median (25th–75th percentile) <1, no. (%) 1–4, no. (%) 5–9, no. (%) 10–14, no. (%) 15–19, no. (%) ≥20, no. (%) |
8.8 (4.5–20.4) 3 (7.0) 8 (18.6) 15 (34.9) 5 (11.6) 1 (2.3) 11 (25.6) |
6.5 (2.8–10.4) 93 (10.1) 270 (29.3) 310 (33.7) 138 (15.0) 55 (6.0) 55 (6.0) |
2.6 (0.5–7.7) 24 (36.4) 18 (27.3) 19 (28.8) 4 (6.1) 1 (1.5) 0 (0.0) |
|
Platelet count, x 103,¶ median (25th–75th percentile) <150, no. (%) ≥150, no. (%) |
185 (139–254) 13 (28.9) 32 (71.1) |
232 (174–284) 170 (17.7) 790 (82.3) |
244 (194–288) 12 (17.1) 58 (82.9) |
|
Albumin, g/L,** median (25th–75th percentile) <35, no. (%) ≥35, no. (%) |
40 (35–42) 9 (21.4) 33 (78.6) |
39 (36–42) 172 (19.3) 717 (80.7) |
39 (36–42) 12 (17.9) 55 (82.1) |
|
ALP, IU/L,†† median (25th–75th percentile) <120, no. (%) 120–179, no. (%) 180–189, no. (%) 190–199, no. (%) 200–299, no. (%) 300–399, no. (%) ≥400, no. (%) |
131 (81–240) 20 (41.7) 12 (25.0) 2 (4.2) 1 (2.1) 5 (10.4) 4 (8.3) 4 (8.3) |
133 (99–189) 393 (40.2) 309 (31.6) 32 (3.3) 21 (2.1) 140 (14.3) 42 (4.3) 40 (4.1) |
106 (77–157) 43 (58.9) 16 (21.9) 1 (1.4) 1 (1.4) 6 (8.2) 4 (5.5) 2 (2.7) |
| Total bilirubin, µmol/L, median (25th–75th percentile)‡‡ | 10.4 (6.5–14.7) | 9.0 (6.1–13.0) | 8.0 (5.8–14.0) |
|
Combined ALP (IU/L) and total bilirubin (µmol/L), no. (%)§§ ALP ≥200 + total bilirubin ≤21 ALP <200 + total bilirubin >21 ALP ≥200 + total bilirubin >21 ALP <200 + total bilirubin ≤21 |
7 (15.6) 2 (4.4) 5 (11.1) 31 (68.9) |
176 (18.5) 41 (4.3) 42 (4.4) 693 (72.8) |
9 (12.9) 5 (7.1) 2 (2.9) 54 (77.1) |
| AST, IU/L, median (25th–75th percentile)¶¶ | 31 (21–62) | 30 (23–41) | 28 (22–43) |
| ALT, IU/L, median (25th–75th percentile)*** | 29 (18–54) | 27 (20–40) | 29 (22–50) |
| GGT, IU/L, median (25th–75th percentile)††† | 118 (40–301) | 62 (31–138) | 66 (25–185) |
Notes: UDCA duration for those currently on UDCA (time from UDCA start date to last visit): median 6.1 years (2.6–9.8) – n = 715;
UDCA duration for those previously on UDCA (time from UDCA to stop date) median 2.2 years (0.8–7.1) – n = 29; current UDCA dose for those currently on UDCA (mg/kg/day): Median 14.0 (12.5–16.0) – n = 694
UDCA = Ursodeoxycholic acid; AMA = Antimitochondrial antibody; ALP = Alkaline phosphatase; AST = Aspartate aminotransferase, ALT = Alanine aminotransferase; GGT = Gamma-glutamyl transferase
* UDCA groups: n = 50, n = 999, n = 73;
† UDCA groups: n = 50, n = 969, n = 71;
‡ UDCA groups; n = 49, n = 973, n = 74;
§ UDCA groups; n = 43, n = 921, n = 66;
¶ UDCA groups; n = 45, n = 960, n = 70;
** UDCA groups, n = 42, n = 889, n = 67;
†† UDCA groups, n = 48, n = 977, n = 73;
‡‡ UDCA groups; n = 45, n = 962, n = 70;
§§ UDCA groups; n = 45, n = 952, n = 70;
¶¶ UDCA groups, n = 41, n = 835, n = 68;
*** UDCA groups; n = 48, n = 989, n = 73
††† UDCA groups; n = 33, n = 815, n = 59